BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Gane, Edward J. ^{[3
]}

Agarwal, Kosh ^{[4
]}

Wong, Grace Lai-Hung C. ^{[5
]}

Lim, Young-Suk ^{[6
]}

Chen, Chi-Yi ^{[7
]}

Lim, Seng Gee ^{[8
]}

Yatsuhashi, Hiroshi ^{[9
]}

Fung, Scott K. ^{[10
]}

Abramov, Frida ^{[11
]}

Wang, Hongyuan ^{[11
]}

Yee, Leland J. ^{[11
]}

Flaherty, John F. ^{[11
]}

Pan, Calvin Q. ^{[12
]}

Marcellin, Patrick ^{[13
]}

机构：

[1] Hosp Univ Vall Dhebron, Barcelona, Spain

[2] Ciberehd Inst Carlos III, Madrid, Spain

[3] Univ Auckland, Auckland, New Zealand

[4] Kings Coll Hosp London, Inst Liver Studies, London, England

[5] Chinese Univ Hong Kong, MDAC, Hong Kong, Peoples R China

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[7] Chiayi Christian Hosp, Chiayi, Taiwan

[8] Natl Univ Hlth Syst, Singapore, Singapore

[9] Natl Hosp Org Nagasaki Med Ctr, Clin Res Ctr, Nagasaki, Japan

[10] Univ Toronto, Dept Med, Toronto, ON, Canada

[11] Gilead Sci Inc, Foster City, CA 94404 USA

[12] NYU, NYU Langone Hlth, Grossman Sch Med, New York, NY USA

[13] Univ Paris, Hop Beaujon, AP HP, Paris, France

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1405C

引用

页码：S507 / S509

页数：3

共 50 条

[31] COMPARATIVE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS
Yu, N. Y.
Chang, K. C.
VALUE IN HEALTH, 2020, 23 : S532 - S532
[32] Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF)
Chuang, Wan-Long
Seto, Wai-Kay
Inokuma, Tetsuro
Ikeda, Fusao
Santantonio, Teresa A.
Flaherty, John F.
Kim, Kyungpil
Gaggar, Anuj
Subramanian, Mani
Habersetzer, Francois
Ramji, Alnoor
Mukewar, Shrikant
Chan, Henry Lik-Yuen
Brunetto, Mau-rizia R.
HEPATOLOGY, 2016, 64 : 916A - 917A
[33] EFFICACY AND SAFETY RESULTS 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) VS CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey H.
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Trinh, Huy N.
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L.
GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1195
[34] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-POSITIVE PATIENTS: A GLOBAL PHASE 3 STUDY
Agarwal, Kosh
Fung, Scott
Seto, Wai-Kay
Lim, Young-Suk
Gane, Edward
Janssen, Harry L.
Chuang, Wan-Long
Bae, Ho
Yoon, Ki Tae
Flaherty, John F.
Lau, Audrey
Gaggar, Anuj
Suri, Vithika
Cathcart, Andrea
Lin, Lanjia
Chan, Alain
Shalimar, Mani Subramanian
Furusyo, Norihiro
Buti, Maria
Chan, Henry L.
GASTROENTEROLOGY, 2017, 152 (05) : S1085 - S1086
[35] IMPACT OF PRE-TREATMENT PLASMA HBV DNA LEVELS ON THE RATE OF ALT NORMALIZATION DURING ANTIVIRAL THERAPY WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR CHRONIC HEPATITIS B (CHB)
Lim, Young-Suk
Choi, Jonggi
Choi, Won-Mook
Brunetto, Maurizia R.
Hou, JinLin
Agarwal, Kosh
Chang, Ting-Tsung
Ning, Qin
Lim, Seng Gee
Streinu-Cercel, Adrian
Flaherty, John F.
Wang, Hongyuan
Gao, Bing
Gaggar, Anuj
Suri, Vithika
Coffin, Carla S.
Ferrety, Maria Asuncion Buti
Chan, Henry Lik Yuen
HEPATOLOGY, 2020, 72 : 485A - 485A
[36] Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks
Chuang, W. L.
Agarwal, K.
Hwang, J. S.
Caruntu, F.
Wong, F.
Hann, H. W.
Flaherty, J.
Lau, A.
Gaggar, A.
Suri, V.
Mo, S.
Subramanian, G. M.
Hui, A. J.
Yatsuhashi, H.
Lim, Y. S.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S695 - S695
[37] Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF)
Goorney, B.
Perez, K.
HIV MEDICINE, 2019, 20 : 39 - 39
[38] TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS
Buti, M.
Hadziyannis, S.
Mathurin, P.
Urbanek, P.
Sherman, M.
Strasser, S.
Wang, C.
Petersen, J.
Heathcote, E. J.
Marcellin, P.
Sorbel, J.
Mondou, E.
Anderson, J.
Rousseau, F.
JOURNAL OF HEPATOLOGY, 2009, 50 : S10 - S11
[39] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS
Chan, Henry Lik Yuen
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
GUT, 2019, 68 : A142 - A143
[40] Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis
Strasser, S. I.
Gane, E. J.
Weilert, F.
Sievert, W.
George, J.
Crawford, D.
Ngu, M. C.
Heathcote, E. J.
Marcellin, P.
Sorbel, J.
Rousseau, F.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A309 - A309

← 1 2 3 4 5 →